Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06037174
Other study ID # SYSKY-2023-472-01
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 15, 2023
Est. completion date September 10, 2025

Study information

Verified date December 2023
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Xiaoming Huang, Professor
Phone 13602808820
Email hxming@mail.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The incidence of thyroid cancer has increased rapidly in recent years, especially in women. Early differentiated thyroid cancer has a good prognosis, and surgery is the main treatment. Traditional open surgery would leave a scar on the neck. However, emerging minimally invasive procedures can avoid the scar on the neck, resulting in better aesthetic effect, which would have an impact on the quality of life of patients to a certain degree. This study intend to follow up patients regularly with early differentiated thyroid cancer undergoing different surgery. The quality of life, voice, scar would be assessed by authoritative questionaires or scales. We hope to demonstrate that minimally invasive surgery is better than traditional open surgery in order to provide reliable evidence for clinical practice.


Description:

The incidence of thyroid cancer has increased rapidly in recent years, especially in women. Differentiated thyroid cancer takes the largest proportion in thyroid cancer, but it has a good prognosis. For early differentiated thyroid cancer, surgery is the main treatment. Traditional open surgery would leave a scar on the neck, which is especially troublesome for female patients. However, emerging minimally invasive procedures, such as endoscopy-assisted subclavian approach, robot-assisted transaxillary or transoral approach, etc., can avoid the scar on the neck, resulting in better aesthetic effect, which would have an impact on the quality of life of patients to a certain degree. This study intend to follow up patients regularly with early differentiated thyroid cancer undergoing surgery according to a prospective cohort design. The evaluation questionnaires including quality of life, voice and scar would be completed to demonstrate that minimally invasive surgery is better than traditional open surgery not only in the way of effectiveness, but also in the quality of life. We hope to provide reliable evidence for clinical practice by this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 230
Est. completion date September 10, 2025
Est. primary completion date September 10, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Age =18 years and < 70 years; - Biopsy or surgical pathology indicated differentiated thyroid carcinoma (papillary thyroid carcinoma, follicular carcinoma); - stage T1~T3a, N0~N1a, M0; - Ability to read and write Chinese; - Willingness to follow up. Exclusion Criteria: - Age < 18 years old or =70 years old; - Biopsy or surgical pathology indicated medullary carcinoma or anaplastic thyroid carcinoma; - Aggressive histology: tall cell, columnar cell, hobnail variant, etc. - Mixed with medullary carcinoma or anaplastic thyroid carcinoma; - High risk of recurrence (according to ATA guideline); - Lateral cervical lymph node metastasis or distant metastasis; - Suffer from other malignant tumors; - History of thyroid surgery or cervical lymph node dissection; - Cognition or behavior impairment.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
minimally invasive procedure
different minimally invasive approach to complete thyroidectomy, including endoscopy-assisted subclavian approach, robot-assisted transaxillary or transoral approach (not leaving scar on the neck)

Locations

Country Name City State
China Sun Yat-sen Memorial Hopsital Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary change of quality of life (SF-36) change of the scores of the SF-36(36-item Short-Form)questionaire baseline, 1month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery
Primary change of quality of life (Thyca-Qol) change of the scores of the Thyca-Qol(Thyroid Cancer-specific Quality of Life) questionaire baseline, 1month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery
Secondary voice handicap index assessment of quality of voice baseline, 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery
Secondary scores of the surgical scar scores of the questionaires (POSAS) about scar 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery
Secondary level of thyroglobulin an indicator to monitor tumor residual or recurrence baseline, 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery
Secondary level of calcium to indicate whether the patient have hypocalcemia baseline, 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery
Secondary operation duration time for operation Intraoperative
Secondary blood loss blood loss during operation up to 1 week after surgery
Secondary postoperative drainage drainage volume after surgery up to 1 week after surgery
Secondary complications complication events after surgery, e.g. hoarseness, hypocalcemia, hemorrhage, seroma baseline, 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery
Secondary satisfaction of the surgery Visual Analog Score for satisfaction 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05774535 - Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
Withdrawn NCT04224792 - Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors N/A
Completed NCT01728623 - A Study of E7080 in Subjects With Advanced Thyroid Cancer Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT02911155 - Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Recruiting NCT05025046 - NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
Not yet recruiting NCT03978351 - The Role of Midkine in Diagnosis of Thyroid Cancer
Completed NCT02658513 - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Completed NCT02375451 - Effect of Childhood Radioiodine Therapy on Salivary Function N/A
Withdrawn NCT01994200 - Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients Phase 1/Phase 2
Terminated NCT01403324 - Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer N/A
Completed NCT00970359 - Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 N/A
Completed NCT00439478 - Dental Safety Profile of High-Dose Radioiodine Therapy Phase 4
Completed NCT00223158 - Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer N/A
Active, not recruiting NCT03246958 - Nivolumab Plus Ipilimumab in Thyroid Cancer Phase 2
Active, not recruiting NCT04544111 - PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Phase 2
Completed NCT04876287 - Salivary dysfuncTion After Radioiodine Treatment
Recruiting NCT06073223 - Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer N/A
Recruiting NCT04952493 - Anlotinib or Penpulimab in Combination With RAI for DTC Phase 2